A practical reference on alpha-MSH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
=== Lotion === Lotions are similar to solution but are thicker and tend to be more emollient in nature than the solution. They are usually oil mixed with water, and more often than not have less alcohol than solution. Lotions can be drying if they contain a high amount of alcohol.
=== Universities === Nilamber-Pitamber University, India National Penghu University of Science and Technology, Taiwan Northwestern Polytechnical University, China Northwestern Polytechnic University, the former name of San Francisco Bay University, California, United States North Park University, Chicago, Illinois, United States
== Background == Albericio earned his Ph.D. in chemistry from the University of Barcelona in 1981. He became a full professor at the University of Barcelona in 1995 and later served as executive director of the Barcelona Science Park from 2005 to 2012, where he was involved in field of biotechnology entrepreneurship. From 2014 to 2015, he served as the founding rector of Yachay Tech University in Ecuador. Since 2016, he has been affiliated with the University of KwaZulu-Natal in South Africa as a research professor. Albericio’s research focuses on the development of methodologies for the synthesis of peptides and other bioactive compounds. He has contributed to the design and commercialization of numerous reagents and materials used in peptide synthesis, including ChemMatrix resin and OxymaPure. Albericio was honored with the Lifetime Achievement Award at the 2024 European Peptide Synthesis Conference (EPSC) in the Czech Republic, in recognition of his contributions to the field of peptide synthesis. He also serves a editor of the International Journal of Peptide Research and Therapeutics and as a Councillor for the American Peptide Society. Throughout his career, Albericio has published extensively, with over 900 scientific articles. He has a high number of citations to his work (49,559) and an h-index of 107.
==== Components ==== Water: Water makes up around 80% of cartilage. Chondrocytes: Chondrocytes are the cells that produce and maintain the cartilaginous matrix. They are sparsely dispersed throughout cartilage and make up only about 2% of the total volume of cartilage. Chondrocytes vary in size, shape and concentration depending on their location in articular cartilage. Collagen: Collagen is a structural protein present in the extracellular matrix of cartilage. Collagen is composed of a triple helix structure of polypeptide chains and offers shear and tensile properties to the cartilage. Type II collagen is the most common type of collagen present in cartilage though types IX, X, XI, and XIV are also present. Overall, collagen is a stabilizing protein present in the ECM. Proteoglycans: Proteoglycans are the second most abundant macromolecule in the ECM of cartilage. Proteoglycans consist of a linker protein along with a core protein to which glycosaminoglycans (GAGs) attach. The most common GAGs are chondroitin sulfate and keratin sulfate. Proteoglycans attach to a central chain, usually hyaluronic acid, via a linker protein, to create larger proteoglycan aggregates. Proteoglycans are hydrophilic and therefore attract and restrain water molecules. This provides cartilage with its intrinsic ability to resist compression. Glycoproteins: Many other glycoproteins are present in cartilage ECM in small amounts that help maintain structure and organization. Specifically, lubricin helps to create a lubricating surface on the cartilage for easier joint mobility.
Sources: en.wikipedia.org
The two got official approval from Valve to release Sven Co-op on Steam as a standalone title in 2012, though opted to wait nearly a year to announce this in July 2013 to give their team time to develop a hotfix for the current version of the mod. This standalone title was released on January 22, 2016, and includes all the assets for Half-Life required to play that game without installing the original game; players are still required to have purchased and installed Opposing Force and Blue Shift to play those in the standalone release of Sven Co-op. The standalone version includes updated versions of the Half-Life campaign maps, improved versions of popular maps developed for Sven Co-op, and additional scripting tools that will allow level designers to further customize new maps beyond the default GoldSrc. McDermott stated that their team anticipates continuing to improve tools for level designers, such as being able to replace the game's default heads-up display, though as the game is still developed in the team's free time, there is no information on when these will be available.
The Israeli Coordinator of Government Activities in the Territories closed multiple aid crossings in the Gaza Strip, specifically interrupting free circulation on the Egypt–Gaza border. Israeli forces suspended United Nations humanitarian movements and postponed planned rotations of international humanitarian staff, including medical evacuations and the return of people into Gaza, which the United Nations Office for the Coordination of Humanitarian Affairs condemned. Israeli settler violence against Palestinians in occupied West Bank has increased; settlers have taken advantage of curbs on movement imposed during the renewed Israeli state of emergency. The renewed blocking of West Bank roads in the context of the 2026 Lebanon war has delayed medics from assisting injured Palestinians. The EU stated on 10 March that the Israeli actions were unacceptable and urged the Israeli authorities to make immediate efforts to prevent the violence against Palestinian civilians under international law, warning that "impunity for such acts risks provoking further violence".
(2026) review different models of evolution of European hominins during the Middle Pleistocene (including evolutionary models including all European population in the lineage ancestral to Neanderthals and the models proposing coexistence of multiple contemporaneous lineages in Europe) and the analytical frameworks supporting these models. García-Martínez et al. (2026) report the discovery of a parietal bone from a new paleoanthropological site Ruidera (Spain), providing evidence of variability of cranial morphology of Middle Pleistocene hominins. Yue et al. (2026) report evidence of production of diverse stone tools at the Xigou site (Henan, China) between 160,000 and 72,000 years ago, including evidence of well-organised core reduction strategies, production of diverse small flake-based tools, and hafted implements. The earliest evidence of use of sophisticated, systematic centripetal flaking systems in eastern Asia known to date is reported from the late Middle Pleistocene Lingjing site (Henan, China) by Zhao et al. (2026). Siemssen et al. (2026) report evidence of antibacterial properties of birch tar produced with methods used in Europe during the Middle Paleolithic. Guil-Guerrero (2026) argues that consumption of fly larvae by Neanderthals postulated by Beasley, Lesnik & Speth (2025) does not by itself explain nitrogen isotope enrichment observed in Neanderthal collagen, interpreted as more likely to be primarily caused by targeted hunting and consumption of megafauna by Neanderthals.
To assist with settling on the best form of treatment for cauliflower ear, Yotsuyanagi et al. created a classification system for deciding when surgery is needed and as a guide to what the best approach would be.
== Function == The enzyme catalyses a chemical reaction that produces a specific isomer of cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) from the components guanosine triphosphate (GTP) and adenosine triphosphate (ATP), with two units of pyrophosphate (PPi) as a byproduct:
Sources: en.wikipedia.org
Engrafting an immunodeficient mouse with functional human cells can be achieved by intravenous injections of human cells and tissue into the mouse, and/or creating a genetically modified mouse from human genes. These models have been instrumental in studying human diseases, immune responses, and therapeutic interventions. This section highlights the various humanized mice models developed using the different methods.
Aeroponics is also widely used in laboratory studies of plant physiology and plant pathology. Aeroponic techniques have been given special attention from NASA since a mist is easier to handle than a liquid in a zero-gravity environment.
ERp57 is an enzyme of the thiol oxidoreductase family located in the ER. It is attached to substrates in an indirect fashion through association with the molecular chaperone calreticulin of the peptide-loading complex, In early stages of generation of MHC-I molecules, ERp57 is associated with free MHC-I heavy chains. As a result, its function is determined by the formation of disulfide bonds in heavy chains, by oxidative folding of the heavy chain, and finally by the fact that ERp57 is loading the peptides onto MHC-I molecules.
Confluent and reticulated papillomatosis (confluent and reticulated papillomatosis of Gougerot and Carteaud, familial cutaneous papillomatosis, familial occurrence of confluent and reticulated papillomatosis) Digitate dermatosis Drug-induced keratoderma Exfoliative dermatitis (dermatitis exfoliativa, erythroderma, red man syndrome) Florid cutaneous papillomatosis Granular parakeratosis (axillary granular parakeratosis, intertriginous granular parakeratosis) Keratolysis exfoliativa (lamellar dyshidrosis, recurrent focal palmar peeling, recurrent palmar peeling) Keratosis punctata of the palmar creases (hyperkeratosis penetrans, hyperkeratosis punctata, keratodermia punctata, keratosis punctata, keratotic pits of the palmar creases, lenticular atrophia of the palmar creases, punctate keratosis of the palmar creases) Meesmann corneal dystrophy Paraneoplastic keratoderma Pityriasis rosea (pityriasis rosea Gibert) Pityriasis rubra pilaris (Devergie's disease, lichen ruber acuminatus, lichen ruber pilaris) Pure hair-nail type ectodermal dysplasia Small plaque parapsoriasis (chronic superficial dermatitis) Tripe palms Xanthoerythrodermia perstans
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.